Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Lisdexamfetamine
Elvanse
Routinely available
SMC (863/13)
29/03/2023
Indication
As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate.
Therapeutic Area
Central nervous system
Status Description
Routinely available in line with national guidance
Formulation
30mg, 50mg & 70mg capsules
Comments
-